Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

被引：18
|
作者：
Abou-Alfa, Ghassan K.
Mollon, Patrick
Meyer, Tim
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Kelley, Robin Kate
Baron, Ari David
Benzaghou, Fawzi
Valcheva, Velichka Valerieva
Hazra, Saswati
Mangeshkar, Milan
Freemantle, Nicholas
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] IPSEN, Abingdon, Oxon, England
[3] UCL, Canc Inst, London, England
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[8] Pacific Hem Onc Assoc, Mill Valley, CA USA
[9] IPSEN, Paris, France
[10] Ipsen Pharma SAS, Paris, France
[11] Prometheus Lab Inc, San Diego, CA USA
[12] Exelixis Inc, San Francisco, CA USA
[13] UCL, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
207
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Chen, Yen-Hsun
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Reduction of quality-adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD)
    Yamada, Kazuo
    Kamagata, Eiichiro
    QUALITY OF LIFE RESEARCH, 2017, 26 (11) : 3069 - 3073
  • [34] Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure
    Ozasa, Neiko
    Morimoto, Takeshi
    Furukawa, Yutaka
    Shizuta, Satoshi
    Nishiyama, Kei
    Kita, Toru
    Kimura, Takeshi
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 123 (02) : 213 - 216
  • [35] Quality-of-Life-Adjusted Hazard of Death: A Formulation of the Quality-Adjusted Life-Years Model of Use in Benefit-Risk Assessment
    Garcia-Hernandez, Alberto
    VALUE IN HEALTH, 2014, 17 (02) : 275 - 279
  • [36] Reduction of quality-adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD)
    Kazuo Yamada
    Eiichiro Kamagata
    Quality of Life Research, 2017, 26 : 3069 - 3073
  • [37] COST-EFFECTIVENESS OF TREATING CRITICAL ISCHEMIA USING QUALITY-ADJUSTED LIFE YEARS
    ALLEN, DR
    FERGUS, MEB
    CHANT, ADB
    BRITISH JOURNAL OF SURGERY, 1990, 77 (03) : A348 - A348
  • [38] How Many Quality-Adjusted Life Years Do Patients Operated for CSM Gain?
    Englander, Zachary K.
    Chan, Andrew Kai-Hong
    Yang, Eunice
    Ambati, Vardhaan Sai
    Mummaneni, Praveen V.
    Bisson, Erica Fay
    Bydon, Mohamad
    Asher, Anthony L.
    Coric, Domagoj
    Kim, Paul Keetae
    NEUROSURGERY, 2025, 71 : 142 - 142
  • [39] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Rimassa, Lorenza
    Cicin, Irfan
    Blanc, Jean-Frederic
    Klumpen, Heinz Josef
    Zagonel, Vittorina
    Tran, Albert
    Kim, Stefano Chong Hun
    Lin, Zhong-Zhe
    Tam, Vincent C.
    Hazra, Saswati
    Mangeshkar, Milan
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Rimassa, L.
    Cicin, I
    Blanc, J-F
    Kluempen, H-J
    Zagonel, V
    Tran, A.
    Kim, S.
    Lin, Z-Z
    Tam, V. C.
    Hazra, S.
    Mangeshkar, M.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 283
12345